Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jun;73(12):1581–1587. doi: 10.1038/bjc.1996.298

Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.

A Berruti 1, A Piovesan 1, M Torta 1, C A Raucci 1, G Gorzegno 1, P Paccotti 1, L Dogliotti 1, A Angeli 1
PMCID: PMC2074561  PMID: 8664134

Abstract

Serum bone alkaline phosphatase (BALP), serum carboxy-terminal propeptide of type I procollagen (PICP) and serum bone gla protein (BGP) as markers of bone formation, serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of collagen resorption and fasting molar ratio of urinary calcium to creatinine (CaCr) and serum parathyroid hormone (PTH) were determined in two groups of cancer patients: 48 with advanced or metastatic disease with negative bone scan and 174 with bone metastases categorised as having lytic, mixed or blastic lesions and with more or fewer than or equal to three sites involved. In patients without apparent bone involvement, bone formation markers were rarely elevated. Conversely, serum ICTP was frequently found to be supranormal, showing it to be a non-specific marker for early detection of bone metastases. As expected, values of bone formation markers progressively increased in patients with lytic, mixed and blastic lesions, but ICTP levels did not show any differences according to the types of bone appearances, confirming previous reports of elevated osteoclast activity also in patients with apparent blastic lesions. Serum PTH increased significantly in patients with lytic compared with patients with mixed and blastic appearances, paralleling the bone formation markers, but CaCr showed the opposite pattern. These data are compatible with calcium entrapment in the bone in patients with increased osteoblast activity. This so called 'bone hunger syndrome' is further confirmed by the finding that in the subgroup of blastic appearances CaCr diminished whereas both ICTP and PTH increased according to the extent of tumour load in the bone.

Full text

PDF
1581

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azria M. The value of biomarkers in detecting alterations in bone metabolism. Calcif Tissue Int. 1989 Jul;45(1):7–11. doi: 10.1007/BF02556653. [DOI] [PubMed] [Google Scholar]
  2. Campbell F. C., Blamey R. W., Woolfson A. M., Elston C. W., Hosking D. J. Calcium excretion (CaE) in metastatic breast cancer. Br J Surg. 1983 Apr;70(4):202–204. doi: 10.1002/bjs.1800700405. [DOI] [PubMed] [Google Scholar]
  3. Clarke N. W., McClure J., George N. J. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991 Jul;68(1):74–80. doi: 10.1111/j.1464-410x.1991.tb15260.x. [DOI] [PubMed] [Google Scholar]
  4. Coleman R. E., Woll P. J., Miles M., Scrivener W., Rubens R. D. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer. 1988 Nov;58(5):621–625. doi: 10.1038/bjc.1988.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Delmas P. D. Biochemical markers of bone turnover. J Bone Miner Res. 1993 Dec;8 (Suppl 2):S549–S555. doi: 10.1002/jbmr.5650081323. [DOI] [PubMed] [Google Scholar]
  6. Hanson D. A., Weis M. A., Bollen A. M., Maslan S. L., Singer F. R., Eyre D. R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 1992 Nov;7(11):1251–1258. doi: 10.1002/jbmr.5650071119. [DOI] [PubMed] [Google Scholar]
  7. Hosking D. J. Advances in the management of Paget's disease of bone. Drugs. 1990 Dec;40(6):829–840. doi: 10.2165/00003495-199040060-00005. [DOI] [PubMed] [Google Scholar]
  8. Jacobs S. C. Spread of prostatic cancer to bone. Urology. 1983 Apr;21(4):337–344. doi: 10.1016/0090-4295(83)90147-4. [DOI] [PubMed] [Google Scholar]
  9. Melkko J., Niemi S., Risteli L., Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 1990 Jul;36(7):1328–1332. [PubMed] [Google Scholar]
  10. Moro L., Gazzarrini C., Crivellari D., Galligioni E., Talamini R., de Bernard B. Biochemical markers for detecting bone metastases in patients with breast cancer. Clin Chem. 1993 Jan;39(1):131–134. [PubMed] [Google Scholar]
  11. Paterson C. R., Robins S. P., Horobin J. M., Preece P. E., Cuschieri A. Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer. 1991 Nov;64(5):884–886. doi: 10.1038/bjc.1991.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Peacock M., Robertson W. G., Nordin B. E. Relation between serum and urinary calcium with particular reference to parathyroid activity. Lancet. 1969 Feb 22;1(7591):384–386. doi: 10.1016/s0140-6736(69)91353-1. [DOI] [PubMed] [Google Scholar]
  13. Pecherstorfer M., Zimmer-Roth I., Schilling T., Woitge H. W., Schmidt H., Baumgartner G., Thiébaud D., Ludwig H., Seibel M. J. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 1995 Jan;80(1):97–103. doi: 10.1210/jcem.80.1.7829646. [DOI] [PubMed] [Google Scholar]
  14. Riancho J. A., Arjona R., Valle R., Sanz J., González-Macías J. The clinical spectrum of hypocalcaemia associated with bone metastases. J Intern Med. 1989 Dec;226(6):449–452. doi: 10.1111/j.1365-2796.1989.tb01423.x. [DOI] [PubMed] [Google Scholar]
  15. Rico H., Uson A., Hernandez E. R., Prados P., Paramo P., Cabranes J. A. Hyperparathyroidism in metastases of prostatic carcinoma: a biochemical, hormonal and histomorphometric study. Eur Urol. 1990;17(1):35–39. doi: 10.1159/000463996. [DOI] [PubMed] [Google Scholar]
  16. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993 Apr;39(4):635–640. [PubMed] [Google Scholar]
  17. Stewart A. F., Broadus A. E. Clinical review 16: Parathyroid hormone-related proteins: coming of age in the 1990s. J Clin Endocrinol Metab. 1990 Dec;71(6):1410–1414. doi: 10.1210/jcem-71-6-1410. [DOI] [PubMed] [Google Scholar]
  18. Terzolo M., Piovesan A., Osella G., Pia A., Reimondo G., Pozzi C., Raucci C., Torta M., Paccotti P., Angeli A. Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment. Calcif Tissue Int. 1993 Mar;52(3):188–191. doi: 10.1007/BF00298716. [DOI] [PubMed] [Google Scholar]
  19. Uebelhart D., Gineyts E., Chapuy M. C., Delmas P. D. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner. 1990 Jan;8(1):87–96. doi: 10.1016/0169-6009(91)90143-n. [DOI] [PubMed] [Google Scholar]
  20. Urwin G. H., Percival R. C., Harris S., Beneton M. N., Williams J. L., Kanis J. A. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol. 1985 Dec;57(6):721–723. doi: 10.1111/j.1464-410x.1985.tb07040.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES